Bio Rad Laboratories Inc
BIO300.930USD
+1.070+0.36%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
8.12BMarket Cap
LossP/E TTM
More Details of Bio Rad Laboratories Inc Company
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
Bio Rad Laboratories Inc Info
Ticker SymbolBIO
Company nameBio Rad Laboratories Inc
IPO dateMar 17, 1980
CEOSchwartz (Norman D)
Number of employees7700
Security typeOrdinary Share
Fiscal year-endMar 17
Address1000 Alfred Nobel Dr
CityHERCULES
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code94547
Phone15107247000
Websitehttps://www.bio-rad.com/
Ticker SymbolBIO
IPO dateMar 17, 1980
CEOSchwartz (Norman D)
Company Executives of Bio Rad Laboratories Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Norman D. Schwartz
Mr. Norman D. Schwartz
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.39M
+214.86%
Ms. Colleen Corey
Ms. Colleen Corey
Executive Vice President, Global Human Resources
Executive Vice President, Global Human Resources
19.55K
+5.80%
Mr. Sedat Evran
Mr. Sedat Evran
Executive Vice President - Global Supply Chain
Executive Vice President - Global Supply Chain
2.02K
+53.88%
Mr. Jonathan P. (Jon) Divincenzo
Mr. Jonathan P. (Jon) Divincenzo
President, Chief Operating Officer
President, Chief Operating Officer
919.00
--
Ms. Eva Anette Engelhardt
Ms. Eva Anette Engelhardt
Executive Vice President, President of Clinical Diagnostics Group
Executive Vice President, President of Clinical Diagnostics Group
896.00
+470.70%
Mr. Gregory K. (Greg) Hinckley, CPA
Mr. Gregory K. (Greg) Hinckley, CPA
Lead Independent Director
Lead Independent Director
808.00
+61.60%
Ms. Courtney C Enloe
Ms. Courtney C Enloe
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
612.00
+414.29%
Mr. Arnold A. Pinkston
Mr. Arnold A. Pinkston
Independent Director
Independent Director
308.00
--
Mr. Jeffrey L. (Jeff) Edwards
Mr. Jeffrey L. (Jeff) Edwards
Independent Director
Independent Director
308.00
--
Ms. Melinda Litherland
Ms. Melinda Litherland
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Norman D. Schwartz
Mr. Norman D. Schwartz
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.39M
+214.86%
Ms. Colleen Corey
Ms. Colleen Corey
Executive Vice President, Global Human Resources
Executive Vice President, Global Human Resources
19.55K
+5.80%
Mr. Sedat Evran
Mr. Sedat Evran
Executive Vice President - Global Supply Chain
Executive Vice President - Global Supply Chain
2.02K
+53.88%
Mr. Jonathan P. (Jon) Divincenzo
Mr. Jonathan P. (Jon) Divincenzo
President, Chief Operating Officer
President, Chief Operating Officer
919.00
--
Ms. Eva Anette Engelhardt
Ms. Eva Anette Engelhardt
Executive Vice President, President of Clinical Diagnostics Group
Executive Vice President, President of Clinical Diagnostics Group
896.00
+470.70%
Mr. Gregory K. (Greg) Hinckley, CPA
Mr. Gregory K. (Greg) Hinckley, CPA
Lead Independent Director
Lead Independent Director
808.00
+61.60%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
266.90M
40.96%
Europe
217.20M
33.33%
APAC
126.40M
19.40%
Other
41.10M
6.31%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 30
Updated: Sun, Nov 30
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
First Eagle Investment Management, L.L.C.
11.50%
The Vanguard Group, Inc.
8.17%
Alice N. Schwartz Revocable Trust
8.13%
BlackRock Institutional Trust Company, N.A.
6.77%
Schwartz (Norman D)
6.36%
Other
59.06%
Shareholders
Shareholders
Proportion
First Eagle Investment Management, L.L.C.
11.50%
The Vanguard Group, Inc.
8.17%
Alice N. Schwartz Revocable Trust
8.13%
BlackRock Institutional Trust Company, N.A.
6.77%
Schwartz (Norman D)
6.36%
Other
59.06%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
43.38%
Investment Advisor
40.44%
Individual Investor
8.25%
Corporation
8.13%
Hedge Fund
5.13%
Research Firm
1.16%
Bank and Trust
1.15%
Pension Fund
1.14%
Sovereign Wealth Fund
0.63%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
1040
20.58M
101.60%
-3.97K
2025Q3
1095
20.58M
103.17%
+603.60K
2025Q2
1114
19.81M
108.02%
-855.27K
2025Q1
1146
19.96M
99.31%
-2.83M
2024Q4
1140
19.39M
101.48%
-657.49K
2024Q3
1121
20.03M
101.42%
-386.71K
2024Q2
1139
20.32M
91.46%
+1.29M
2024Q1
1154
19.07M
91.02%
-2.25M
2023Q4
1187
19.09M
89.28%
-259.69K
2023Q3
1170
19.31M
88.28%
-552.69K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
First Eagle Investment Management, L.L.C.
2.52M
11.45%
+223.05K
+9.72%
Jun 30, 2025
The Vanguard Group, Inc.
1.84M
8.38%
-59.61K
-3.13%
Jun 30, 2025
Alice N. Schwartz Revocable Trust
1.78M
8.1%
--
--
May 01, 2025
BlackRock Institutional Trust Company, N.A.
1.54M
7.02%
-98.58K
-6.00%
Jun 30, 2025
Schwartz (Norman D)
447.98K
2.04%
+5.20K
+1.17%
Sep 06, 2025
Dimensional Fund Advisors, L.P.
999.57K
4.55%
+122.53K
+13.97%
Jun 30, 2025
Veritas Asset Management LLP
863.14K
3.92%
-49.98K
-5.47%
Jun 30, 2025
Ariel Investments, LLC
818.62K
3.72%
+93.96K
+12.97%
Jun 30, 2025
EARNEST Partners, LLC
605.89K
2.75%
+6.26K
+1.04%
Jun 30, 2025
State Street Investment Management (US)
584.37K
2.66%
-110.15K
-15.86%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Parnassus Value Select ETF
3.94%
First Trust Indxx Medical Devices ETF
2.15%
ROBO Global Healthcare Technology & Innovation ETF
1.61%
Schwab Ariel Opportunities ETF
1.6%
First Trust Health Care Alphadex Fund
1.49%
FPA Global Equity ETF
1.38%
First Eagle Global Equity ETF
1.21%
iShares Health Innovation Active ETF
1.17%
Pacer US Export Leaders ETF
1.03%
Harbor Health Care ETF
0.82%
View more
Parnassus Value Select ETF
Proportion3.94%
First Trust Indxx Medical Devices ETF
Proportion2.15%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.61%
Schwab Ariel Opportunities ETF
Proportion1.6%
First Trust Health Care Alphadex Fund
Proportion1.49%
FPA Global Equity ETF
Proportion1.38%
First Eagle Global Equity ETF
Proportion1.21%
iShares Health Innovation Active ETF
Proportion1.17%
Pacer US Export Leaders ETF
Proportion1.03%
Harbor Health Care ETF
Proportion0.82%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Bio Rad Laboratories Inc?
The top five shareholders of Bio Rad Laboratories Inc are:
First Eagle Investment Management, L.L.C. holds 2.52M shares, accounting for 11.45% of the total shares.
The Vanguard Group, Inc. holds 1.84M shares, accounting for 8.38% of the total shares.
Alice N. Schwartz Revocable Trust holds 1.78M shares, accounting for 8.10% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.54M shares, accounting for 7.02% of the total shares.
Schwartz (Norman D) holds 447.98K shares, accounting for 2.04% of the total shares.
First Eagle Investment Management, L.L.C. holds 2.52M shares, accounting for 11.45% of the total shares.
The Vanguard Group, Inc. holds 1.84M shares, accounting for 8.38% of the total shares.
Alice N. Schwartz Revocable Trust holds 1.78M shares, accounting for 8.10% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.54M shares, accounting for 7.02% of the total shares.
Schwartz (Norman D) holds 447.98K shares, accounting for 2.04% of the total shares.
What are the top three shareholder types of Bio Rad Laboratories Inc?
The top three shareholder types of Bio Rad Laboratories Inc are:
First Eagle Investment Management, L.L.C.
The Vanguard Group, Inc.
Alice N. Schwartz Revocable Trust
First Eagle Investment Management, L.L.C.
The Vanguard Group, Inc.
Alice N. Schwartz Revocable Trust
How many institutions hold shares of Bio Rad Laboratories Inc (BIO)?
As of 2025Q4, 1040 institutions hold shares of Bio Rad Laboratories Inc, with a combined market value of approximately 20.58M, accounting for 101.60% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.58%.
What is the biggest source of revenue for Bio Rad Laboratories Inc?
In FY2025Q2, the -- business generated the highest revenue for Bio Rad Laboratories Inc, amounting to -- and accounting for --% of total revenue.
